GlaxoSmithKline LLC 2024-01-03 Health moderate FDA
Health · FDA · Recall #FDA-D-0160-2024
ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder) 62.5 mcg/25mcg. 1 inhaler… Recall
Issued January 3, 2024 · GlaxoSmithKline LLC
In January 2024, GlaxoSmithKline LLC recalled the ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder) 62.5 mcg/25mcg. 1 inhaler…, a moderate health recall reported by the FDA.
Compiled by Maya Ellison, RecallCheckr
What this means for you
Failed Release Testing: Coarse Particle Mass for umeclidinium Out of Specification
What you should do
- 1 Stop using ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder) 62.5 mcg/25mcg. 1 inhaler… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact GlaxoSmithKline LLC to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- GlaxoSmithKline LLC
- Category
- Health
- Recall date
- January 3, 2024
- Units affected
- Not reported
- Sold at
- Distributed Nationwide in the USA and Puerto Rico.
- Recall number
- FDA-D-0160-2024
- Made in
- United States
- Issuing agency
- FDA
In context
- GlaxoSmithKline LLC has 3 recalls in our database.
- We're tracking 3,576 Health recalls in our database.
- This is the 737th Health recall we've logged in 2024.